Tanfanercept

特那西普

Report date: 2026/04/29 20:02:18

Base Information

Drug NameTanfanercept
Drug Alias NameTNF-alpha blocker - HanAll BiopharmaTanfanercept - HanAll BiopharmaAnti-TNF-alpha protein - HanAll BiopharmaHL-036HBM-9036 +[7] 
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsXerophthalmia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth KoreaMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesHanall
China Registration ClassN/A

Develop Information

Active CompaniesHarbour BiomedHanAll Biopharma Co LtdHarbour Biomed Therapeutics Ltd +[6] 
Inactive CompaniesN/A
Active IndicationsXerophthalmia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A